Global Intravenous (IV) Iron Drugs Market Expected To Reach XX Million By 2025

2018-05-14 11:57:10

Intravenous Iron Drugs Market Overview
According to a new report published by Reports Monitor titled, “Intravenous (IV) Iron Drugs Market by Product Type, and Therapeutic Application: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the intravenous iron drugs market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025. 

Iron is by far the most substantial elements needed by the human body. It encompasses major part of haemoglobin and carries oxygen all through the body. Iron also truly contributes in various fundamental biological processes such as metabolism, formation of myoglobin, neurotransmitter production, formation of collagen and immune system function. Inadequate supply of iron to the body mainly causes iron deficiency anaemia associated with increased mortality and morbidity. It stated by Vitamin and Mineral Nutrition Information System in 2017, approximately 30% of anemia in children and women in developing nations is because of iron deficiency. 

More Insightful Information | Request a Sample Copy @

Rising incidences of iron deficiency increase in chronic kidney diseases patients undergoing dialysis, growing diabetic population and unmet medical requirement attributes to the growth of global intravenous iron drugs market. Furthermore, increased awareness regarding personal care, development in healthcare system, technological advancement in IV iron drugs further fuels the growth of the market. Considering iron deficiency phenomenon more popular in women due to heavy menstruation and excessive bleeding during childbirth gynaecology segment stands as vital therapeutic application leading further growth of the market. However, adverse side effects pertaining to IV drugs and stringent government regulations limit the growth of the market. Emerging countries are showing their interest in producing advanced IV drugs that consolidates better opportunities for small market players.

Intravenous iron drug market growth in North America is positively influenced by increasing predominance of iron deficient anaemia, increased awareness, rising expenses on healthcare and presence of market key players in the geography.

The global market of IV drugs in segmented considering various product types, based on product type it is divided into four sections Ferric carboxyl maltose, iron sucrose, iron dextran, and ferric gluconate. Furthermore on the basis of therapeutic application it is classified into nephrology, cardiology, gynaecology, oncology, gastroenterology, surgeries and chronic heart failures.

Competitive Landscape
Owing presence of well-established firms and emergence of new entrants in the market, the global intravenous iron drug market is witnessing huge competition. Major operating players in the market include Galenica, AMAG Pharmaceuticals, Inc., PHARMACOSMOS A/S, Allergan PLC, Daichi Sankyo Company Ltd., Nippon Shinyaku Co. Ltd., Sanofi, Rockwell Medical Technologies, Inc., Fresenius Medical Care AG & Co. and Luitpold Pharmaceuticals, Inc.,

About Garner Insights:

We at Garner provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.

Contact Us:

Kevin Thomas


+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected] 

Related Press Releases